Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.12
Bid: 5.74
Ask: 6.50
Change: -0.12 (-1.92%)
Spread: 0.76 (13.24%)
Open: 6.24
High: 0.00
Low: 0.00
Prev. Close: 6.24
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

27 Oct 2020 08:35

RNS Number : 3233D
Synairgen plc
27 October 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Synairgen plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Bong Koh and Nimish Shah (as the voting members of VHCP Management II, LLC and VHCP Management III, LLC)

 

City and country of registered office (if applicable)

New York, NY, U.S.A.

4. Full name of shareholder(s) (if different from 3.)v

Name

See section 11 below

City and country of registered office (if applicable)

New York, NY, U.S.A.

5. Date on which the threshold was crossed or reachedvi:

23 October 2020

6. Date on which issuer notified (DD/MM/YYYY):

27 October 2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

3.91%

3.91%

165,104,676

Position of previous notification (if

applicable)

4.64%

4.64%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

ISIN: GB00B0381Z20

6,455,000

3.91%

SUBTOTAL 8. A

6,455,000

3.91%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Bong Koh and Nimish Shah (as the voting members of VHCP Management II, LLC and VHCP Management III, LLC)

3.91%

N/A

3.91%

Bong Koh and Nimish Shah (as the votingmembers of VHCP Management II, LLC)

 

N/A

N/A

N/A

VHCP Management II, LLC

 

N/A

N/A

N/A

Bong Koh and Nimish Shah (as the votingmembers of VHCP Management III, LLC)

 

N/A

N/A

N/A

VHCP Management III, LLC

 

N/A

N/A

N/A

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Bong Koh and Nimish Shah are the voting members of VHCP Management II, LLC and VHCP Management III, LLC.

 

VCHP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and manager of VHCP Co-Investment Holdings II, LLC, each of which holds shares in Synairgen plc falling below the notifiable threshold.

 

VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and manager of VHCP Co-Investment Holdings III, LLC, each of which holds shares in Synairgen plc falling below the notifiable threshold.

 

All percentages are based on the notified current issued share capital of Synairgen plc of 165,104,676 ordinary shares.

 

 

 

Place of completion

New York, NY, U.S.A.

Date of completion

27 October 2020

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFIFVTIVLDFII
Date   Source Headline
25th Jan 20217:00 amRNSInclusion in US ACTIV-2 trial
20th Jan 20217:00 amRNSHome trial recruitment completed
13th Jan 20217:00 amRNSFirst Patient Dosing in Phase III SG018 Trial
6th Jan 20215:10 pmRNSHolding(s) in Company
5th Jan 20215:53 pmRNSHolding(s) in Company
18th Dec 20207:00 amRNSCOVID-19 Clinical Programme Update
10th Dec 202012:57 pmRNSHolding(s) in Company
13th Nov 20205:03 pmRNSHolding(s) in Company
13th Nov 20207:00 amRNSLancet Respiratory Medicine publishes Phase 2 data
10th Nov 20201:47 pmRNSHolding(s) in Company
4th Nov 20205:51 pmRNSHolding(s) in Company
3rd Nov 20209:00 amRNSHolding(s) in Company
2nd Nov 202012:20 pmRNSResult of General Meeting and Total Voting Rights
2nd Nov 20207:00 amRNSResult of Open Offer
28th Oct 202011:20 amRNSHolding(s) in Company
27th Oct 20208:35 amRNSHolding(s) in Company
21st Oct 20209:45 amRNSHolding(s) in Company
21st Oct 20209:40 amRNSHolding(s) in Company
16th Oct 20203:10 pmRNSExercise of Options and Total Voting Rights
15th Oct 20205:35 pmRNSExercise of Options and Total Voting Rights
15th Oct 20201:51 pmRNSDirector/PDMR Shareholding
15th Oct 20207:00 amRNSResults of Placing
14th Oct 20205:32 pmRNSPlacing and Open Offer
12th Oct 202011:05 amRNSSecond Price Monitoring Extn
12th Oct 202011:00 amRNSPrice Monitoring Extension
6th Oct 20208:55 amRNSHolding(s) in Company
2nd Oct 20207:00 amRNSAppointment of Joint Broker
1st Oct 20202:06 pmRNSSecond Price Monitoring Extn
1st Oct 20202:00 pmRNSPrice Monitoring Extension
1st Oct 202011:00 amRNSPrice Monitoring Extension
29th Sep 20207:00 amRNSClinigen signs MAP agreement with Synairgen
29th Sep 20207:00 amRNSSynairgen and Clinigen sign Managed Access Program
29th Sep 20207:00 amRNSInterim results for six months ended 30 June 2020
9th Sep 20207:00 amRNSSynairgen IP Update
8th Sep 20207:00 amRNSPositive interim analysis of SNG001 in COPD
7th Sep 20203:53 pmRNSHolding(s) in Company
3rd Sep 20205:58 pmRNSHolding(s) in Company
1st Sep 20204:41 pmRNSSecond Price Monitoring Extn
1st Sep 20204:36 pmRNSPrice Monitoring Extension
24th Aug 20204:41 pmRNSSecond Price Monitoring Extn
24th Aug 20204:36 pmRNSPrice Monitoring Extension
21st Aug 20205:28 pmRNSHolding(s) in Company
13th Aug 20204:41 pmRNSSecond Price Monitoring Extn
13th Aug 20204:35 pmRNSPrice Monitoring Extension
13th Aug 20207:57 amRNSHolding(s) in Company
10th Aug 20209:50 amRNSHolding(s) in Company
7th Aug 20208:22 amRNSHolding(s) in Company
5th Aug 20205:51 pmRNSHolding(s) in Company
31st Jul 20208:37 amRNSHolding(s) in Company
29th Jul 20204:43 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.